Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: Findings from the Breast Cancer Surveillance Consortium

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 2822-2828

  Menes, Tehillah S ^a,b   Kerlikowske, Karla ^c   Jaffer, Shabnam ^b   Seger, Deborah ^d   Miglioretti, Diana L ^d,e  

^a ELMHURST HOSPITAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERPLASIA; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS;

EID: 72749084840     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0745     Document Type: Article

References (27)

1. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-2708
2. Stomper PC, Cholewinski SP, Penetrante RB, Harlos JP, Tsangaris TN. Atypical hyperplasia: frequency andmammographic and pathologic relationships in excisional biopsies guided with mammography and clinical examination. Radiology 1993;189:667-671
3. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151 (Pubitemid 15192861)
4. Page DL, Dupont WD. Anatomic markers of human premalignancy andrisk of breast cancer. Cancer 1990;66:1326-1335
5. Page DL. Breast lesions, pathology andcancer risk. Breast J 2004;10:S3-4.
6. Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia. Results from the Nurses' Health Study. Cancer 2007;109:180-187
7. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005;205:248-254
8. Viacava P, Naccarato AG, Bevilacqua G. Different proliferative patterns characterize different preinvasive breast lesions. J Pathol 1999;288:245-251 (Pubitemid 29317765)
9. Abdel-Fatah TM, Powe DG, Hodi Z, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma andinvasive lobular carcinoma. Am J Surg Pathol 2007;31:417-426
10. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton L. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006;24:e49-50.
11. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-1674
12. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age andtu mor characteristics among U.S. women. Breast Cancer Res 2007;9:R28. (Pubitemid 350214681)
13. Fleming ID, Cooper JS, Henson DE, et al, editors. AJCC cancer staging manual. 5th edPhilad elphia (PA): Lippincott-Raven; 1997.
14. Webb PM, Byrne C, Schnitt SJ, et al. Family history of breast cancer, age andbenign breast disease. Int J Cancer 2002;100:375-378 (Pubitemid 34728999)
15. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med2005;353:229-237
16. Rohan TE, Negassa A, Rowan T, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev 2008;17:2337-2343
17. Friedenreich CM, Bryant HE, Alexander F, Hugh J, Danyluk J, Page DL. Risk factors for benign proliferative breast disease. Int J Epidemiol 2000;29:637-644 (Pubitemid 30612229)
18. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, et al. Epithelial atypia in biopsies performedfor microcalcifications. Practical considerations about 2,833 serially sectionedsu rgical biopsies with a long follow-up. Virchows Arch 2007;451:1-10.
19. Eby PR, Ochsner JE, DeMartini WB, Allison KH, Peacock S, Lehman CD. Frequency and upgrade rates of atypical ductal hyperplasia diagnosedat stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge. AJR Am J Roentgenol 2009;192:229-234
20. Fowble B, Hanlon AL, Patchefsky A, et al. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treatedwith conservative surgery and radiation. Int J Radiat Oncol Biol Phys 1998;42:105-115 (Pubitemid 28435603)
21. Colditz GA. Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin. Breast Cancer Res 2007;9:108.
22. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-430 (Pubitemid 351172118)
23. Glass AG, Lacey JV, Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1986-2006: combined roles of menopausal hormone therapy, screening mammography andestrogen receptor status. J Natl Cancer Inst 2007;99:1152-1161
24. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA. Declines in invasive breast cancer anduse of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99:1335-1339 (Pubitemid 47394172)
25. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer andmammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253
26. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screenedpopulation. J Clin Oncol 2003;21:4314-4321
27. Rohan TE, Negassa A, Chlebowski RT, et al. Conjugatedequine estrogen and risk of benign proliferative breast disease: a randomized controlledtrial. J Natl Cancer Inst 2008;100:563-571